Case Study

How Collaboration Helped A Global Biopharma Fast-Track Novel Molecule Development For Global Licensing

iStock-596767998-lab-team-discussion-teamwork

A global biopharma company partnered with Syngene for Bioanalytical studies for PK, ADA and NAb assays. In less than a year of the collaboration, the company decided to make Syngene, its preferred CRO lab for a novel molecule for migraine. The molecule went on to receive FDA approval in 2018.

Bolstered by the success of this project, the company recommended Syngene to its co-development partner, a global, pharma company. The result was a 3-way partnership between the biopharma company, their co-development partner and Syngene for supporting clinical trials with Pharmacokinetics, Immunogenicity and Neutralizing antibody data using the biopharma company’s proprietary methods.

Today, besides expanding its collaboration with the biopharma company, Syngene is working with their co-development partner on 3 novel molecules and 9 clinical studies.

Needless to say, the programs discussed in this case study are excellent examples of how a Pharma-CRO partnership can extend beyond company borders into wholistic drug development activities for global licensing.

VIEW THE CASE STUDY!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Outsourced Pharma? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: